Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.33 |
| ▸ | CDK9 | P50750 | 4/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL828523 | 0.86 | P2RX7 (0.39) | HTR1ASLC6A2SLC6A4CCNT1CDK9 | |
| SCHEMBL828872 | 0.83 | HTR1A (0.32) | HTR1ASLC6A2SLC6A4CCNT1CDK9 | |
| SCHEMBL828722 | 0.81 | IDH1 (0.38) | HTR1ASLC6A2SLC6A4P2RX7CYP19A1 | |
| SCHEMBL829120 | 0.77 | NPY5R (0.34) | P2RX7CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL828718 | 0.76 | CYP11B2 (0.43) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL828879 | 0.75 | CCNT1 (0.32) | CNR2CCNT1CDK9CYP19A1CYP11B1 | |
| SCHEMBL828687 | 0.68 | CYP19A1 (0.38) | HTR1ASLC6A2SLC6A4P2RX7RORC | |
| SCHEMBL828908 | 0.68 | P2RX7 (0.40) | P2RX7 | |
| SCHEMBL9419279 | 0.66 | CCNT1 (0.38) | HTR1ASLC6A2SLC6A4CCNT1CDK9 | |
| SCHEMBL828499 | 0.66 | HTR1A (0.40) | HTR1ASLC6A2SLC6A4P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143403-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20120010402-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010402-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | CNR2 66/4885HTR1A 239/4885SLC6A2 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.